162 related articles for article (PubMed ID: 31800510)
1. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization.
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Saltarelli A; Marino Marsilia G; Cianni R; Schillaci O; Bagni O
Nucl Med Commun; 2020 Jan; 41(1):78-86. PubMed ID: 31800510
[TBL] [Abstract][Full Text] [Related]
2. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors.
Soydal C; Kucuk ON; Bilgic S; Ibis E
Ann Nucl Med; 2016 Jan; 30(1):29-34. PubMed ID: 26370716
[TBL] [Abstract][Full Text] [Related]
5. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.
Camacho JC; Kokabi N; Xing M; Schuster DM; Kim HS
Clin Nucl Med; 2014 Nov; 39(11):944-50. PubMed ID: 25140563
[TBL] [Abstract][Full Text] [Related]
6.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
7. Repeated Treatment with
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
[No Abstract] [Full Text] [Related]
8. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
9.
Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
Wagemans MEHM; Kunnen B; Stella M; van Rooij R; Smits M; Bruijnen R; Lam MGEH; de Jong HWAM; Braat AJAT
J Nucl Med; 2024 Feb; 65(2):272-278. PubMed ID: 38176716
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.
Hwang JP; Moon JH; Kim HK; Lee MH; Lim CH; Park SB; Yoon JK; Park JM
Medicine (Baltimore); 2021 May; 100(21):e26015. PubMed ID: 34032720
[TBL] [Abstract][Full Text] [Related]
12. Differences on metabolic behavior between intra and extrahepatic cholangiocarcinomas at
Sabaté-Llobera A; Gràcia-Sánchez L; Reynés-Llompart G; Ramos E; Lladó L; Robles J; Serrano T; Mestres-Martí J; Gámez-Cenzano C
Clin Transl Oncol; 2019 Mar; 21(3):324-333. PubMed ID: 30022384
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
14. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
Levillain H; Duran Derijckere I; Ameye L; Guiot T; Braat A; Meyer C; Vanderlinden B; Reynaert N; Hendlisz A; Lam M; Deroose CM; Ahmadzadehfar H; Flamen P
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2270-2279. PubMed ID: 31324943
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between
Seo S; Yoh T; Morino K; Fuji H; Taura K; Fukumitsu K; Ishii T; Nakamoto Y; Kaido T; Uemoto S
Anticancer Res; 2019 Jan; 39(1):341-346. PubMed ID: 30591478
[TBL] [Abstract][Full Text] [Related]
16. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
[TBL] [Abstract][Full Text] [Related]
17. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
18. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.
Yugawa K; Itoh S; Iseda N; Kurihara T; Kitamura Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Yoshizumi T; Mori M
Sci Rep; 2021 Mar; 11(1):5845. PubMed ID: 33712681
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of Prognostic Impact of Tumor SUVmax by
Yoh T; Seo S; Morino K; Fuji H; Ikeno Y; Ishii T; Taura K; Nakamoto Y; Higashi T; Kaido T; Uemoto S
World J Surg; 2019 May; 43(5):1323-1331. PubMed ID: 30680501
[TBL] [Abstract][Full Text] [Related]
20. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
